Description

CJC-1295 DAC Peptide

CJC-1295 DAC is a synthetic research peptide studied in endocrine and growth hormone signaling models. It is designed as a long acting analog of growth hormone releasing hormone and engineered for extended stability in circulation. Researchers use this peptide to study sustained growth hormone and IGF-1 dynamics under controlled laboratory conditions.

Product Overview

CJC-1295 DAC is built from a 29 amino acid sequence derived from the active region of native growth hormone releasing hormone. This sequence represents the shortest functional fragment shown to stimulate growth hormone release from pituitary somatotroph cells.

Key structural modifications improve durability and persistence in research models.

Primary research focus areas include

• Growth hormone secretion patterns
• IGF-1 signaling pathways
• Pituitary receptor activation
• Long acting peptide pharmacokinetics
• Endocrine system modeling

What Makes CJC-1295 DAC Different

CJC-1295 DAC includes a Drug Affinity Complex modification. This feature links the peptide to plasma proteins, which extends circulation time and supports prolonged observation windows in research settings.

Key differentiators

• Extended half life measured in days
• Plasma protein binding through DAC technology
• Sustained receptor engagement
• Reduced enzymatic degradation

Mechanism of Action

CJC-1295 DAC binds to growth hormone releasing hormone receptors on pituitary somatotroph cells. This interaction initiates intracellular signaling associated with growth hormone synthesis and release.

Observed signaling features

• Activation of G protein coupled pathways
• Increased cyclic adenosine monophosphate signaling
• Enhanced transcription of growth hormone related genes
• Secondary stimulation of insulin like growth factor one production

IGF-1 acts as a downstream mediator of growth hormone signaling and plays a central role in tissue growth and protein synthesis studies.

Research Findings and Observations

Laboratory and preclinical studies describe sustained elevation of growth hormone and IGF-1 following exposure to CJC-1295 DAC.

Reported research observations

• Increased average growth hormone levels over multiple days
• Enhanced growth hormone pulse amplitude
• Prolonged elevation of IGF-1 above baseline
• Cumulative signaling effects after repeated exposure

Animal model studies also describe normalization of growth patterns in models with impaired endogenous GHRH signaling.

Body Composition and Cellular Research

CJC-1295 DAC is examined for its role in anabolic signaling pathways related to tissue structure and maintenance.

Areas of investigation

• Lean mass preservation
• Muscle tissue hypertrophy signaling
• Bone structure support
• Pituitary cell activity and gene expression

Research models show increased pituitary RNA and growth hormone mRNA expression, supporting continued interest in somatotroph cell dynamics.

Peptide Stability and Half Life Design

The peptide sequence includes four targeted amino acid substitutions designed to improve resistance to enzymatic breakdown.

Structural stability features

• Improved protection against dipeptidyl peptidase activity
• Reduced oxidation risk
• Enhanced molecular integrity
• DAC mediated half life extension to multiple days

These features distinguish CJC-1295 DAC from short acting GHRH analogs.

Chemical Information

Molecular formula
C152H252N44O42

Molecular weight
3367.95 g/mol

Other known names

• CJC-1295 with DAC
• DAC GRF
• Long acting GHRH analog

Research Use Disclaimer

For laboratory research only.
Not intended for human consumption, medical treatment, or diagnostic use. Handle only in controlled research environments and follow institutional safety protocols.

External references

Product and Research Information

• Learn how CJC-1295 with DAC works and its lasting activity from Peptide Initiative: CJC‑1295 DAC mechanism, GHRH receptor action
• Technical peptide details and molecular data: CJC‑1295 with DAC technical profile
• Overview of clinical study results and GH/IGF-1 response: CJC‑1295 clinical results database
• Biochemical summary and receptor interaction from Peptpedia: CJC‑1295 research peptide overview
• Structural and stability details from biotech analysis: CJC‑1295 DAC explained structure & mechanism

Supplemental Reference

• Additional product specification and handling guidance (research-focused): CJC‑1295 DAC peptide information from GHPeptides

 

Certificate of analysis